scholarly journals Neurofilament light protein levels in cerebrospinal fluid predict long-term disability of Guillain-Barré syndrome: A pilot study

2018 ◽  
Vol 138 (2) ◽  
pp. 143-150 ◽  
Author(s):  
M. Axelsson ◽  
M. Sjögren ◽  
O. Andersen ◽  
K. Blennow ◽  
H. Zetterberg ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Pilot Study ◽  
Guillain Barre Syndrome ◽  
Neurofilament Light ◽  
Protein Levels ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports

2020 ◽  
Vol 5 ◽  
pp. 107 ◽  
Author(s):  
Rodrigo M. Carrillo-Larco ◽  
Carlos Altez-Fernandez ◽  
Sabrina Ravaglia ◽  
Joaquín A. Vizcarra
Keyword(s):  
Systematic Review ◽  
Cerebrospinal Fluid ◽  
Case Reports ◽  
Epidemiological Studies ◽  
Preliminary Evidence ◽  
Guillain Barre Syndrome ◽  
Protein Levels ◽  
Guillain Barré Syndrome ◽  
Successful Resolution ◽  
Guillain Barré

Background: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and COVID-19. Methods: Without any restrictions, we searched MEDLINE, Embase, Global Health, Scopus, Web of Science and MedXriv (April 23 rd, 2020). Two reviewers screened and studied titles, abstracts and reports. We extracted information to characterize sociodemographic variables, clinical presentation, laboratory results, treatments and outcomes. Results: Eight reports (n=12 patients) of GBS and COVID-19 were identified; one was a Miller Fisher case. The age ranged between 23 and 77 years, and there were more men (9/102). GBS symptoms started between 5 and 24 days after those of COVID-19. The protein levels in cerebrospinal fluid samples ranged between 40 and 193 mg/dl. None of the cerebrospinal fluid samples tested positive for COVID-19. Six patients debuted with ascendant weakness and three with facial weakness. Five patients had favourable evolution, four remained with relevant symptoms or required critical care and one died; the Miller Fisher case had successful resolution. Conclusions: GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.

scholarly journals COVID-19 and Guillain-Barre Syndrome: a systematic review of case reports

2020 ◽  
Vol 5 ◽  
pp. 107 ◽  
Author(s):  
Rodrigo M. Carrillo-Larco ◽  
Carlos Altez-Fernandez ◽  
Sabrina Ravaglia ◽  
Joaquín A. Vizcarra
Keyword(s):  
Systematic Review ◽  
Cerebrospinal Fluid ◽  
Case Reports ◽  
Epidemiological Studies ◽  
Preliminary Evidence ◽  
Guillain Barre Syndrome ◽  
Protein Levels ◽  
Guillain Barré Syndrome ◽  
Successful Resolution ◽  
Guillain Barré

Background: Guillain-Barre Syndrome (GBS) is a neurological autoimmune disease that can lead to respiratory failure and death. Whether COVID-19 patients are at high risk of GBS is unknown. Through a systematic review of case reports, we aimed to summarize the main features of patients with GBS and COVID-19. Methods: Without any restrictions, we searched MEDLINE, Embase, Global Health, Scopus, Web of Science and MedXriv (April 23rd, 2020). Two reviewers screened and studied titles, abstracts and reports. We extracted information to characterize sociodemographic variables, clinical presentation, laboratory results, treatments and outcomes. Results: Eight reports (n=12 patients) of GBS and COVID-19 were identified; one was a Miller Fisher case. Overall, the median age was 62.5 (interquartile range (IQR)=54.5-70.5) years, and there were more men (9/102). GBS symptoms started between 5 and 24 days after those of COVID-19. The median protein levels in cerebrospinal fluid samples was 101.5 mg/dl (IQR=51-145). None of the cerebrospinal fluid samples tested positive for COVID-19. Six patients debuted with ascendant weakness and three with facial weakness. Five patients had favourable evolution, four remained with relevant symptoms or required critical care and one died; the Miller Fisher case had successful resolution. Conclusions: GBS is emerging as a disease that may appear in COVID-19 patients. Although limited, preliminary evidence appears to suggest that GBS occurs after COVID-19 onset. Practitioners and investigators should have GBS in mind as they look after COVID-19 patients and conduct research on novel aspects of COVID-19. Comparison with GBS patients in the context of another viral outbreak (Zika), revealed similarities and differences that deserves further scrutiny and epidemiological studies.

Relationship Between Cerebrospinal Fluid Protein Levels and Electrophysiologic Abnormalities in Guillain–Barré Syndrome

2015 ◽  
Vol 17 (2) ◽  
pp. 47-51 ◽  
Author(s):  
Daniel B. DiCapua ◽  
Amanda A. Lakraj ◽  
Richard J. Nowak ◽  
Kimberly Robeson ◽  
Jonathan Goldstein ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Guillain Barre Syndrome ◽  
Protein Levels ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Cerebrospinal Fluid Protein

Cerebrospinal fluid proteome profile in patients with Guillain-Barre syndrome

2006 ◽  
Vol 33 (S 1) ◽  
Author(s):  
V. Lehmensiek ◽  
S.D. Süßmuth ◽  
G. Tauscher ◽  
S. Felk ◽  
F. Gillardon ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Proteome Profile ◽  
Guillain Barré

Long-term impact on work and private life after Guillain–Barré syndrome

2002 ◽  
Vol 201 (1-2) ◽  
pp. 13-17 ◽  
Author(s):  
Robert A.J.A.M Bernsen ◽  
Aeiko E.J de Jager ◽  
Paul I.M Schmitz ◽  
Frans G.A van der Meché
Keyword(s):  
Private Life ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Long Term Impact

Study of Guillain-Barre syndrome etiology in Pakistani patients

2021 ◽  
Author(s):  
Rashid Iqbal ◽  
Muhammad Javaid Asad ◽  
Saima Siddiqi ◽  
Raja Tahir Mahmood ◽  
Muhamamd Baseer Shah ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Nerve Conduction ◽  
Treatment Strategies ◽  
Guillain Barre Syndrome ◽  
Clinical Feature ◽  
Interleukin 17 ◽  
Healthy Controls ◽  
Female Ratio ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Objective: To examine clinical features, biochemical markers, demographic features, antecedent infections, frequency and treatment strategies. Methods: This case-control study was conducted at Pakistan Institute of Medical Sciences (PIMS), Islamabad, Pakistan and District Headquarters Hospital (DHQ), Rawalpindi, Pakistan from 2018 to 2020. Ninety consecutive patients of Guillain-Barré syndrome (GBS) and 77 healthy controls were enrolled. Patients were diagnosed by clinical presentation, Nerve conduction study (NCS), Electromyography (EMG), Cerebrospinal fluid analysis (CSF) and biochemical profile. Data was analyzed on IBM SPSS version 23. Results: Symmetrical ascending weakness was the striking clinical feature. Mean age was 40.20±14.90 years and male to female ratio was 2.1:1. Acute inflammatory demyelinating polyneuropathy (AIDP) was found to be the most common electrophysiological variant of GBS (46%). There was considerable difference in Interleukin-17(IL-17) levels between GBS patients 23.12 ± 3.41 pg/ml and healthy controls 8.82 ± 2.49. Mean IL-17 level was markedly increased in GBS patients, P=0.006, P<0.05. Gastrointestinal infection was the most common preceding infection (56.66%). Mean CSF protein was 100.83 g/dl with ± 51.32 standard deviation and albumio cytologic dissociation (ACD) was different in all four variants of GBS, P= 0.005. Conclusion: GBS was presented by all ages. Males were more affected than females. About two third of GBS patients showed an antecedent infection before GBS onset. Increased levels of cytokine (IL-17) showed involvement of autoimmunity. ACD differentiated it from poliomyelitis. Plasmapheresis and intravenous immunoglobulin (IVIG) therapy were used to treat patients. Key words: Guillain-Barré Syndrome; cerebrospinal fluid; albuminocytologic dissociation; nerve conduction studies; variants; electromyography Continuous....

scholarly journals A Case Report of a Patient with Guillain-Barre Syndrome Who Complained of Quadriplegia

2021 ◽  
Vol 42 (5) ◽  
pp. 1009-1019
Author(s):  
Gi-yoon Heo ◽  
Chan Lee ◽  
Im-hak Cho ◽  
Hee-kyung Kang ◽  
Min-hwa Kim ◽  
...  
Keyword(s):  
Muscle Weakness ◽  
Muscle Function ◽  
Hospital Admissions ◽  
Combined Treatment ◽  
Gait Pattern ◽  
Guillain Barre Syndrome ◽  
Poor Prognostic Factor ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

Purpose: The aim of this study was to report the improvement of Guillain-Barre syndrome after long-term combination treatment with Korean medicine.Methods: A patient was diagnosed with Guillain-Barre syndrome and treated with herbal medicine, acupuncture, pharmacopuncture, moxibustion, and exercise, including quadruped walking after three hospital admissions. To evaluate muscle strength and weakness, we measured manual muscle function, gait pattern, and the speed of quadruped walking.Results: The patient's muscle weakness in the extremities and gait stance were improved. The speed of quadruped walking was increased.Conclusion: We consider that combined treatment with Korean medicine might be effective for the muscle weakness of Guillain-Barre syndrome with a poor prognostic factor. To verify the effectiveness of this treatment, further research is needed.

Sign in / Sign up

Export Citation Format

Share Document